Will the Phase 2 trial "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL" reach primary completion on or before Jul 8, 2029?

Resolves Yes if ClinicalTrials.gov record NCT06792825 (Masonic Cancer Center, University of Minnesota) shows an actual primary completion date on or before Jul 8, 2029. Registered date at generation: Jul 8, 2029.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Jul 8, 2029, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.